CSTL

Insider Trades

Name	Value	Action	Price	Current Price
Maetzold Derek JDirector, Officer: Pres. & Chief Exec. Officer $28k1.4k shares SellJun 15, 2026 $20.66 $20.25
Maetzold Derek JDirector, Officer: Pres. & Chief Exec. Officer $24k1.2k shares SellJun 15, 2026 $20.66 $20.25
Maetzold Derek JDirector, Officer: Pres. & Chief Exec. Officer $11k550 shares SellJun 15, 2026 $20.66 $20.25
Cole G BradleyDirector $76k2.7k shares SellMar 5, 2026 $28.51 --
Cole G BradleyDirector $135k4.7k shares SellMar 5, 2026 $28.44 --
Stokes FrankChief Financial Officer $168k6k shares SellMar 5, 2026 $27.98 --

News

prnewswire.comCastle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)prnewswire.comJun 19

prnewswire.comFirst Patient Enrolled in New Study Assessing early prediction of flares in Atopic Dermatitis by Castle Biosciences in Collaboration with SciBaseprnewswire.comJun 10

prnewswire.comCastle Biosciences to Present at the 2026 Jefferies Global Healthcare Conferenceprnewswire.comMay 13

prnewswire.comCastle Biosciences' AdvanceAD-Tx™ Test Receives 2026 MedTech Breakthrough Award for Genomics Innovationprnewswire.comMay 12

seekingalpha.comCastle Biosciences, Inc. (CSTL) Q1 2026 Earnings Call Transcriptseekingalpha.comMay 7

Trade CSTL

About Castle Biosciences, Inc.

Castle Biosciences, Inc. functions as a commercial-stage diagnostics firm, with its primary objective being the provision of both diagnostic and prognostic testing services, specifically targeting various dermatological cancers. Their flagship product, DecisionDx-Melanoma, represents an advanced multi-gene expression profile (GEP) assay engineered to assess the probability of metastasis in patients afflicted with invasive cutaneous melanoma. In addition to their leading solution, the company has created several other specialized, proprietary tests. Among these is DecisionDx-UM, a GEP test tailored to forecast the risk of metastasis for individuals with uveal melanoma, a less common malignancy of the eye. Another key offering is DecisionDx-SCC, a distinctive 40-gene expression profile test that utilizes a patient's unique tumor biology to predict their specific risk of squamous cell carcinoma metastasis, particularly for those presenting with recognized risk factors. Moreover, they offer DecisionDx DiffDx-Melanoma and myPath Melanoma, both proprietary GEP tests employed to assist in the accurate diagnosis of ambiguous pigmented lesions. These specialized testing services are provided by Castle Biosciences to patients predominantly through their healthcare providers. The organization commenced operations in 2007 and maintains its corporate headquarters in Friendswood, Texas.

CEO: Derek J. Maetzold
IPO Date: Jul 25, 2019

Market Data

Open: $20.39
High: $21.15
Low: $20.23
Volume: 705K
Avg Volume: 380K
52W High: $44.28
52W Low: $14.59

Valuation

Market Cap: $641M
Enterprise Value: $614M
Dividend Yield: 0.00%

Financials

Free Cash Flow: $28M
Revenue: $344M
Net Income: $-24M
Cash: $117M
Debt: $37M

Events

EarningsAug 3

EPS est. -0.38